1. Home
  2. BEAM vs TENB Comparison

BEAM vs TENB Comparison

Compare BEAM & TENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$31.65

Market Cap

2.8B

Sector

Health Care

ML Signal

HOLD

Logo Tenable Holdings Inc.

TENB

Tenable Holdings Inc.

HOLD

Current Price

$22.48

Market Cap

2.7B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
BEAM
TENB
Founded
2017
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
2.7B
IPO Year
2020
2018

Fundamental Metrics

Financial Performance
Metric
BEAM
TENB
Price
$31.65
$22.48
Analyst Decision
Buy
Buy
Analyst Count
14
18
Target Price
$46.00
$38.12
AVG Volume (30 Days)
2.0M
1.4M
Earning Date
02-24-2026
02-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$55,701,000.00
$974,603,000.00
Revenue This Year
N/A
$12.22
Revenue Next Year
$26.52
$7.62
P/E Ratio
N/A
N/A
Revenue Growth
N/A
11.05
52 Week Low
$13.53
$21.55
52 Week High
$36.44
$45.45

Technical Indicators

Market Signals
Indicator
BEAM
TENB
Relative Strength Index (RSI) 56.44 37.91
Support Level $29.80 $21.55
Resistance Level $35.34 $23.35
Average True Range (ATR) 2.80 0.62
MACD 0.14 0.07
Stochastic Oscillator 55.79 44.42

Price Performance

Historical Comparison
BEAM
TENB

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

About TENB Tenable Holdings Inc.

Founded in 2002, Tenable is a cybersecurity company that began providing vulnerability management solutions under its Nessus software. In recent years, Tenable has expanded its portfolio to provide a broader range of exposure management modules. Solutions include cloud security and compliance, active directory management, operational technology security and advanced vulnerability analytics. The Maryland-based company went public in 2018.

Share on Social Networks: